A detailed history of Janus Henderson Group PLC transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Janus Henderson Group PLC holds 28,749 shares of BPMC stock, worth $2.79 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
28,749
Previous 29,057 1.06%
Holding current value
$2.79 Million
Previous $2.76 Million 12.41%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$85.18 - $108.78 $26,235 - $33,504
-308 Reduced 1.06%
28,749 $3.1 Million
Q1 2024

May 15, 2024

SELL
$73.17 - $99.79 $73 - $99
-1 Reduced -0.0%
29,057 $2.76 Million
Q4 2023

Feb 14, 2024

SELL
$43.96 - $92.84 $1,934 - $4,084
-44 Reduced 0.15%
29,058 $2.68 Million
Q3 2023

Nov 14, 2023

BUY
$46.9 - $66.0 $187 - $264
4 Added 0.01%
29,102 $1.46 Million
Q2 2023

Aug 14, 2023

BUY
$42.2 - $66.37 $239,147 - $376,118
5,667 Added 24.19%
29,098 $1.84 Million
Q1 2023

May 15, 2023

BUY
$37.97 - $50.0 $464,031 - $611,050
12,221 Added 109.02%
23,431 $1.05 Million
Q3 2022

Nov 14, 2022

BUY
$49.93 - $77.7 $1,198 - $1,864
24 Added 0.21%
11,210 $739,000
Q2 2022

Aug 15, 2022

SELL
$45.23 - $70.15 $768 - $1,192
-17 Reduced 0.15%
11,186 $565,000
Q1 2022

May 16, 2022

BUY
$54.1 - $110.08 $162 - $330
3 Added 0.03%
11,203 $716,000
Q4 2021

Feb 14, 2022

BUY
$94.25 - $115.99 $531,287 - $653,835
5,637 Added 101.33%
11,200 $1.2 Million
Q3 2021

Nov 16, 2021

SELL
$80.98 - $109.47 $764,208 - $1.03 Million
-9,437 Reduced 62.91%
5,563 $572,000
Q4 2017

Feb 09, 2018

BUY
$62.91 - $88.32 $943,650 - $1.32 Million
15,000
15,000 $1.13 Million

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.79B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Janus Henderson Group PLC Portfolio

Follow Janus Henderson Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.